Management of Persistent Anxiety Symptoms

Patient Assessment and Medication Efficacy

A patient recently experienced an anxiety attack severe enough to prompt an emergency department visit with chest pain mimicking myocardial infarction symptoms, and is currently taking venlafaxine 75 mg daily without missed doses, but still experiencing significant anxiety symptoms, indicating that venlafaxine is an appropriate medication choice for anxiety, as serotonin-norepinephrine reuptake inhibitors have demonstrated efficacy in treating anxiety disorders 1
The American Academy of Child and Adolescent Psychiatry suggests that venlafaxine is an appropriate medication choice for anxiety, as SNRIs have demonstrated efficacy in treating anxiety disorders 1

Typically, 2-4 weeks are required to titrate to an efficacious dosage (150-225 mg/day) for optimal effect, according to the Mayo Clinic Proceedings 2

Increase venlafaxine to 150 mg daily, which is considered an adequate trial period for venlafaxine at this dosage, and monitor for response over 4-6 weeks 2
If partial response is achieved but symptoms persist, consider further titration to 225 mg daily, as recommended by the Mayo Clinic Proceedings 3

Monitor blood pressure, as venlafaxine can cause dose-dependent increases in blood pressure, according to the Journal of the American Academy of Child and Adolescent Psychiatry 4
Be cautious about cardiac effects, especially since the patient had chest pain, although not cardiac in origin, as noted in the Mayo Clinic Proceedings 2
Assess for any signs of serotonin syndrome, particularly if the patient is taking other serotonergic medications, as recommended by the Journal of the American Academy of Child and Adolescent Psychiatry 4

If the patient shows less than 30% reduction in anxiety symptoms after an adequate trial at 225 mg/day, consider switching to an alternative first-line medication such as a selective serotonin reuptake inhibitor or duloxetine, as recommended by the Mayo Clinic Proceedings and the Journal of the American Academy of Child and Adolescent Psychiatry 3, 1
Consider combination treatment with cognitive behavioral therapy, which has shown superior efficacy compared to medication alone, according to the Journal of the American Academy of Child and Adolescent Psychiatry 5

Patients should be informed that venlafaxine should never be stopped abruptly due to the risk of discontinuation syndrome, as noted in the Journal of the American Academy of Child and Adolescent Psychiatry 4
If switching medications becomes necessary, cross-tapering is recommended to minimize withdrawal symptoms, according to the Mayo Clinic Proceedings 2

The American College of Physicians suggests that 38% of patients do not achieve treatment response with second-generation antidepressants even after 6-12 weeks, and prolonged trials beyond this timeframe are not supported, with a recommendation to switch to an alternative first-line medication if less than 30% reduction in anxiety symptoms is observed after an adequate trial at 225 mg/day for 4-6 weeks 6, 7, 8
For anxiety accompanying depression, venlafaxine demonstrated superiority over fluoxetine in one trial, with similar timelines for response, as reported by the Annals of Internal Medicine 6, 7, 8